{"entity":{"id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","aka":[],"tldr":"Sarcoma expert who leads Centre Léon Bérard and the French cancer centre network UNICANCER.","summary":"Jean-Yves Blay is Director General of Centre Léon Bérard in Lyon and President of UNICANCER, the French network of cancer centres. His specialisms are sarcoma, GIST, rare cancers and precision oncology, with a focus on the KIT target and imatinib. He coordinates the French NETSARC reference network for sarcomas, and his trials include studies of imatinib duration in GIST and the ProfiLER precision oncology programme. His papers include the ESMO consensus report on the management of gastrointestinal stromal tumours, the INVICTUS phase 3 trial of ripretinib in advanced GIST, and a phase 3 trial comparing doxorubicin alone with intensified doxorubicin plus ifosfamide as first-line treatment for advanced soft-tissue sarcoma. His UNICANCER profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"UNICANCER","url":"https://www.unicancer.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blay%20JY%5BAuthor%5D%20sarcoma"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":["kit"],"drugs":["imatinib"],"companies":["unicancer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General, Centre Léon Bérard, Lyon; President, UNICANCER","institutionId":"unicancer","specialisms":["Sarcoma","GIST","Rare cancers","Precision oncology"],"profiles":[{"label":"UNICANCER","url":"https://www.unicancer.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blay%20JY%5BAuthor%5D%20sarcoma"}],"papers":[{"title":"Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO","journal":"Annals of Oncology","year":2005,"doi":"10.1093/annonc/mdi127"},{"title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(20)30168-6"},{"title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","journal":"The Lancet Oncology","year":2014,"doi":"10.1016/s1470-2045(14)70063-4"},{"title":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPEARHEAD-1+afamitresgene+autoleucel+synovial+sarcoma+Lancet"}],"orcid":"0000-0001-7190-120X"},"route":"/people/jean-yves-blay/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"target":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"}],"company":[{"id":"unicancer","kind":"company","name":"UNICANCER","route":"/companies/unicancer/"}],"idea":[{"id":"idea-bio2-rare-cancer-telepathology-network","kind":"idea","name":"A same-week expert second opinion for every rare cancer diagnosis","route":"/ideas/idea-bio2-rare-cancer-telepathology-network/"},{"id":"idea-bio2-tertiary-lymphoid-induction","kind":"idea","name":"Grow immune command posts inside tumours","route":"/ideas/idea-bio2-tertiary-lymphoid-induction/"}],"paper":[{"id":"paper-spearhead-1-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-lancet-2024/"}],"institution":[{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","route":"/institutions/centre-leon-berard/"}]}}